Oncology Central

How high a bar to change neoadjuvant therapy for triple-negative breast cancer?


Given the association between achievement of a pathologic complete response (pCR) and superior long-term outcomes in triple-negative breast cancer (TNBC), should the standard neoadjuvant regimen for TNBC be updated to reflect results from trials that report higher pCR rates with acceptable toxicity, or should any revision await demonstration of improvements in recurrence-free or overall survival?

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.